Immunology and Biotherapies
27.2K views | +5 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

A safe and potent anti-CD19 CAR T cell therapy

A safe and potent anti-CD19 CAR T cell therapy | Immunology and Biotherapies | Scoop.it
A new anti-CD19 CAR T cell therapy induces potent antitumor responses without causing severe cytokine-release syndrome or neurotoxicity in patients with lymphoma.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

JCM | Thrombin Preconditioning of Extracellular Vesicles Derived from Mesenchymal Stem Cells Accelerates Cutaneous Wound Healing by Boosting Their Biogenesis and Enriching Cargo Co...

JCM | Thrombin Preconditioning of Extracellular Vesicles Derived from Mesenchymal Stem Cells Accelerates Cutaneous Wound Healing by Boosting Their Biogenesis and Enriching Cargo Co... | Immunology and Biotherapies | Scoop.it
Abstract
The aim of this study was to determine the optimal preconditioning regimen for the wound healing therapeutic efficacy of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs). To this end, we compared various preconditioning regimens for both the quantitative and qualitative production of MSC-derived EVs, and their therapeutic efficacy for proangiogenic activity in vitro and cutaneous wound healing in vivo. After preconditioning with thrombin (40 U), H2O2 (50 μM), lipopolysaccharide (1 μg/mL), or hypoxia (10% O2), EV secretion was assessed quantitatively by measuring production per cell and protein quantification, and qualitatively by measuring a proteome profiler and an enzyme-linked immunosorbent assay (ELISA) contained within EVs. The therapeutic efficacy of EVs was assessed in vitro by proliferation, migration and tube formation assays of human umbilical cord blood endothelial cells (HUVECs), and in vivo by quantification of cutaneous wound healing. Thrombin preconditioning optimally boosted EV production and enriched various growth factors including vascular endothelial growth factor and angiogenin contained within EVs compared to other preconditioning regimens. Thrombin preconditioning optimally enhanced proliferation, the migration and tube formation of HUVECs in vitro via pERK1/2 and pAKT signaling pathways, and cutaneous wound healing in vivo compared to other preconditioning regimens. Thrombin preconditioning exhibited optimal therapeutic efficacy compared with other preconditioning regimens in promoting proangiogenic activity in vitro and in enhancing cutaneous wound healing in vivo. These preconditioning regimen-dependent variations in therapeutic efficacy might be mediated by boosting EV production and enriching their cargo content. View Full-Text
Keywords: stem cell; extracellular vesicle; production; microenvironment mimetic
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

In This Issue

In This Issue | Immunology and Biotherapies | Scoop.it
![][1]



Dimethyl fumarate (DMF) is an approved treatment for multiple sclerosis and has been shown to be effective in treating other autoimmune diseases; however, its mechanism of action is poorly understood. In this issue, Zaro et al. (p. [2737][2]) identified a mechanism by which DMF
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Location, location, location: Tissue resident memory T cells in mice and humans

Location, location, location: Tissue resident memory T cells in mice and humans | Immunology and Biotherapies | Scoop.it
Abstract
The discovery of T cells resident in diverse tissues has altered our understanding of adaptive immunity to encompass site-specific responses mediated by tissue-adapted memory T cells throughout the body. Here, we discuss the key phenotypic, transcriptional, and functional features of these tissue-resident memory T cells (TRM) as established in mouse models of infection and translated to humans by novel tissue sampling approaches. Integration of findings from mouse and human studies may hold the key to unlocking the potential of TRM for promoting tissue immunity and preventing infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round

Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round | Immunology and Biotherapies | Scoop.it
The race to bring CAR-T cell therapy to multiple myeloma, a persistent and deadly cancer of the bone marrow, continued on Monday with a fresh round of...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency

Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency | Immunology and Biotherapies | Scoop.it
Biallelic variations in the dedicator of cytokinesis 8 (DOCK8) gene cause a combined
immunodeficiency with eczema, recurrent bacterial and viral infections, and malignancy.
Natural disease outcome is dismal, but allogeneic hematopoietic stem cell transplantation
(HSCT) can cure the disease.
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Cardiorenal complications of immune checkpoint inhibitors

Cardiorenal complications of immune checkpoint inhibitors | Immunology and Biotherapies | Scoop.it
Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy; however, these agents can induce immune-related adverse events (irAEs) in off-target organs. This Review describes the mechanism of action of ICI therapies and how these agents induce irAEs in the kidney and heart.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models | Immunology and Biotherapies | Scoop.it
Most CAR T-cell therapies look for antigens specific to cancer cells. A new approach instead targets the environment around the tumor, using unusually small antibodies made naturally by alpacas, camels and llamas.
more...
No comment yet.
Suggested by LIGHTING
Scoop.it!

Cytokine Circuits in Cardiovascular Disease

The appropriate management of arterial inflammation, a hallmark of atherosclerosis,
represents an unmet therapeutic need for cardiovascular disease patients. Randolph
et al. review the cytokine circuits that underlie the diverse contributions of immune
cells to atherosclerosis and discuss the recent application of these insights in the
form immunotherapy to treat cardiovascular disease.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection
Scoop.it!

CAR T-Cell Therapy | OSUCCC – James

CAR T-Cell Therapy | OSUCCC – James | Immunology and Biotherapies | Scoop.it
CAR T-cell therapy is a type of cellular therapy – a new, proven, leading-edge approach to immunotherapy available right here at the OSUCCC – James.

Via Krishan Maggon
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Gene Therapy Effective for Severe Combined Immunodeficiency

Gene Therapy Effective for Severe Combined Immunodeficiency | Immunology and Biotherapies | Scoop.it
Researchers report they’ve found a way to restore immune function in infants with one form of "bubble boy disease."...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. - PubMed - NCBI

Int J Mol Sci. 2018 Dec 19;19(12). pii: E4118. doi: 10.3390/ijms19124118.Case Reports...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety | Immunology and Biotherapies | Scoop.it
In patients with peanut allergy, high-certainty evidence shows that available peanut
oral immunotherapy regimens considerably increase allergic and anaphylactic reactions
over avoidance or placebo, despite effectively inducing desensitisation.
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. - PubMed - NCBI

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
J Eur Acad Dermatol Venereol. 2019 Apr 22. doi: 10.1111/jdv.15637.[Epub ahead of print]...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Viruses | Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells

Viruses | Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells | Immunology and Biotherapies | Scoop.it
Zika virus (ZIKV), an emerging flavivirus that causes neurodevelopmental impairment to fetuses and has been linked to Guillain-Barré syndrome continues to threaten global health due to the absence of targeted prophylaxis or treatment.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Novel multi‐component vaccine approaches for Burkholderia pseudomallei - Morici - 2019 - Clinical & Experimental Immunology - Wiley Online Library

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Tumors Sweet Success due to Macrophage Polarization

Tumors Sweet Success due to Macrophage Polarization | Immunology and Biotherapies | Scoop.it
This blog discusses a recent study by Bohn et al. (2018) that highlights a mechanism that melanoma utilizes to subvert the immune response.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis - Néel - 2019 - Arthritis & Rheumatology - Wiley Online Library

Original Article Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Antoine Néel MD, PhD Marie Bucchia MD Mélanie Néel Gaelle Tilly Aurélie Caristan MD Michele Yap PhD Sarah Bruneau PhD Marion Cadoux Christian Agard MD, PhD Pascal Godmer MD Sophie Brouard DVM, PhD Mohamed Hamidou MD, PhD Regis Josien MD, PhD Fadi Fakhouri MD, PhD Nicolas Degauque PhD First published: 30 October 2018 The FP7 VISICORT project was supported by the European Union's Seventh Framework Programme for Research, Technological Development and Demonstration (grant 602470). The IHU‐Cesti project was supported by the Nantes Metropole and Pays de la Loire Region as well as the Investments for the Future program (ANR‐10‐IBHU‐005) from the Agence Nationale de la Recherche. The LabEX IGO program was supported by the Investments for the Future program (ANR‐11‐LABX‐0016‐01) from the Agence Nationale de la Recherche. Dr. Antoine Néel's work was supported by the Groupama Loire Bretagne/Fondation Groupama pour la santé. Dr. Caristan's work was supported by the French Internal Medicine Society. Dr. Yap's work was supported by the ProGreffe Foundation (International Fellowship grant). 1Antoine Néel, MD, PhD, Marie Bucchia, MD, Mélanie Néel, Gaelle Tilly, Aurélie Caristan, MD, Marie Rimbert, PharmD, PhD, Sarah Bruneau, PhD, Marion Cadoux, Sophie Brouard, DVM, PhD, Céline Bressollette, MD, PhD, Mohamed Hamidou, MD, PhD, Regis Josien, MD, PhD, Fadi Fakhouri, MD, PhD, Nicolas Degauque, PhD: INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes, France; 2Michele Yap, PhD: CHU Nantes, Nantes, France; 3Christian Agard, MD, PhD: CHU Nantes and CIC biothérapie, Nantes, France; 4Maryvonne Hourmant, MD, PhD: INSERM UMR1064, Université de Nantes and CHU Nantes, Nantes France, and Centre Hospitalier Bretagne Atlantique, Vannes, France; 5Pascal Godmer, MD: Centre Hospitalier Bretagne Atlantique, Vannes, France. No potential conflicts of interest relevant to this article were reported. Abstract Objective To compare the effects of rituximab (RTX) and conventional immunosuppressants (CIs) on CD4+ T cells, Treg cells, and CD8+ T cells in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods A thorough immunophenotype analysis of CD4+, Treg, and CD8+ cells from 51 patients with AAV was performed. The production of cytokines and chemokines by CD8+ T cells stimulated in vitro was assessed using a multiplex immunoassay. The impact of AAV B cells on CD8+ T cell response was assessed using autologous and heterologous cocultures. Results CD4+ and Treg cell subsets were comparable among RTX‐treated and CI‐treated patients. In contrast, within the CD8+ T cell compartment, RTX, but not CIS, reduced CD45RA+CCR7– (TEMRA) cell frequency (from a median of 39% before RTX treatment to 10% after RTX treatment [P < 0.01]) and efficiently dampened cytokine/chemokine production (e.g., the median macrophage inflammatory protein 1α level was 815 pg/ml in patients treated with RTX versus 985 pg/ml in patients treated with CIs versus 970 pg/ml in those with active untreated AAV [P < 0.01]). CD8+ T cell subsets cocultured with autologous B cells produced more proinflammatory cytokines in AAV patients than in controls (e.g., for tumor necrosis factor–producing effector memory CD8+ T cells: 14% in AAV patients versus 9.2% in controls [P < 0.05]). In vitro disruption of AAV B cell–CD8+ T cell cross‐talk reduced CD8+ T cell cytokine production, mirroring the reduced CD8+ response observed ex vivo after RTX treatment. Conclusion The disruption of a pathogenic B cell/CD8+ T cell axis may contribute to the efficacy of RTX in AAV. Further studies are needed to determine the value of CD8+ T cell immunomonitoring in B cell–targeted therapies. Volume71, Issue4 April 2019 Pages 641-650
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells | Immunology and Biotherapies | Scoop.it
A small number of HIV-1–infected individuals develop broadly neutralizing antibodies to the virus (bNAbs). These antibodies are protective against infection in animal models. However, they only emerge 1–3 yr after infection, and show a number of highly unusual features including exceedingly high levels of somatic mutations. It is therefore not surprising that elicitation of protective immunity to HIV-1 has not yet been possible. Here we show that mature, primary mouse and human B cells can be edited in vitro using CRISPR/Cas9 to express mature bNAbs from the endogenous Igh locus. Moreover, edited B cells retain the ability to participate in humoral immune responses. Immunization with cognate antigen in wild-type mouse recipients of edited B cells elicits bNAb titers that neutralize HIV-1 at levels associated with protection against infection. This approach enables humoral immune responses that may be difficult to elicit by traditional immunization.
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells | Journal for ImmunoTherapy of Cancer | Full Text

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells | Journal for ImmunoTherapy of Cancer | Full Text | Immunology and Biotherapies | Scoop.it
Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administered into the patient with the aim to induce a tumor-specific immune response.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Cancer-Specific Antigens Encoded in "Junk" DNA

Cancer-Specific Antigens Encoded in "Junk" DNA | Immunology and Biotherapies | Scoop.it
Researchers found that allegedly noncoding genetic material carries the instructions for many peptides that may help harness the immune system to fight cancer.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Home : Translating Gene and Cell Therapies

Home : Translating Gene and Cell Therapies | Immunology and Biotherapies | Scoop.it
Nature - the world's best science and medicine on your desktop...
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring | Immunology and Biotherapies | Scoop.it
A systematic proteomic investigation of disease mediators secreted by pancreatic stellate cells identifies leukaemia inhibitory factor (LIF) as a key factor that acts on cancer cells, promoting tumour progression and chemoresistance.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Recharting the Course of Sickle Cell Disease – Who will Benefit?

Recharting the Course of Sickle Cell Disease – Who will Benefit? | Immunology and Biotherapies | Scoop.it
Ethical principles of health equity and justice must be examined as these new therapies are developed and progress to first-in-human clinical trials.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors | Immunology and Biotherapies | Scoop.it
Purpose: Patients with relapsed pediatric solid tumors and CNS malignancies have few therapeutic options and frequently die of their disease. Chimeric antigen receptor (CAR) T cells have shown tremendous success in treating relapsed pediatric acute lymphoblastic leukemia, but this has not yet...
more...
No comment yet.